Special Issue

Coronaviruses: Past, Present, and Future

Message from the Guest Editor

Currently, the Omicron variant of SARS-CoV-2 and its subvariants, which are pretty different from the original strain or other previous variants in many respects. Omicron has the innate ability to evade the therapeutic antibodies and immune protection from prior COVID-19 infection and vaccination. Most worryingly, Omicron has shown no sign of slowing down and continues to rapidly mutate and generate new subvariants with immune-evasive properties like BA.5, BQ.1, BA.2.75.2, and XBB. Despite these headwinds, we have had vaccines and treatments available against COVID-19, despite reduced efficacy towards emerging variants. Improvements are still warranted toward the understanding of coronavirus infection and the new prophylaxis and therapeutic agents that can rapidly pivot to combat new viral variants or even new viruses that might drive the next pandemic. For this Special Issue, we will be excited to see the advances, thoughts, and experiences related to the coronavirus family. Original research or review articles are warmly welcomed.

Guest Editor

Dr. Qibin Geng
Department of Pharmacology, Minneapolis, University of Minnesota, Minneapolis, MN 55455, USA

Deadline for manuscript submissions

closed (31 January 2024)

Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/156128

Microorganisms
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microorganisms@mdpi.com

mdpi.com/journal/microorganisms

Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/microorganisms

About the Journal

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Editor-in-Chief

Dr. Nico Jehmlich
Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

MDPI